Lv2
110 积分 2025-07-29 加入
Ifebemtinib plus garsorasib as first-line treatment for KRASG12C-mutated non-small-cell lung cancer in China: a multicentre, single-arm expansion cohort from a phase 1b/2 trial
15天前
已完结
乳腺癌AC-T化疗方案致骨髓抑制的危险因素分析及其风险预测模型的构建
1个月前
已关闭
Preliminary activity and safety results of KRAS G12C inhibitor glecirasib (JAB-21822) in patients with pancreatic cancer and other solid tumors
1个月前
已关闭
Efficacy and safety of garsorasib in patients with KRAS G12C-mutated advanced pancreatic cancer
1个月前
已完结
A HER3-targeting antibody–drug conjugate for leptomeningeal metastasis
4个月前
已完结
Bevacizumab in combination with paclitaxel and platinum for previously treated advanced thymic epithelial tumors
5个月前
已完结
Cisplatin, doxorubicin, and cyclophosphamide plus thoracic radiation therapy for limited-stage unresectable thymoma: an intergroup trial
5个月前
已完结
Therapeutic options in thymomas and thymic carcinomas
5个月前
已完结
Thymoma and thymic carcinomas
5个月前
已关闭
Glecirasib plus sitneprotafib in patients with KRASG12C-mutated non-small-cell lung cancer in China: an open-label, multicentre, single-arm, phase 1/2a trial
5个月前
已完结
皖公网安备34019202002308
